Daniel Claassen, MD (PROGRAM CHAIR)
Associate Professor, Neurology
Richard B. Dewey, Jr., MD
Professor, Neurology and Neurotherapeutics
Director, Clinical Center for Movement Disorders
UT Southwestern Medical Center
This enduring activity will cover treating and managing patients with Parkinson’s Disease.
This enduring activity is intended for U.S.-based neurologists and primary care providers involved in the management of patients with PD, such as internists, family physicians, physician assistants, nurses, nurse practitioners, social workers, physical therapists, occupational therapists, and speech and language pathologists.
On completing the program, attendees should be able to:
- Explain how a deeper understanding of the pathophysiology of PD can translate to more timely and accurate recognition and treatment
- Review the mechanisms of action and clinical profiles of approved and emerging treatment approaches for the management of patients with PD
- Develop individualized management plans for patients with PD that include a multidisciplinary team-based approach
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in treating and managing patients with advanced Parkinson’s Disease.
Credits: 1.0 ANCC Contact Hour
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
|Daniel Claassen, MD||Research Funding||Vaccinex, CHDI, HDSA, Griffin Foundation, Genentech, Wave Life Sciences, Neurocrine, Teva, AbbVie, Biogen|
|Consultant||Neurocrine, Wave Life Science, Teva Pharmaceuticals, Acadia, Alterity, Genetech/Roche, Lundbeck|
|Richard B. Dewey, Jr., MD||Consultant||Supernus Pharmaceuticals and Amneal Pharmaceuticals|
|Research Funding||Clene Nanomedicine, Inc|
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
Chris Drury, MD, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Submit the pre- and post-test and evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making experience before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: November 18, 2020
EXPIRATION DATE: November 18, 2021
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITY ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the event at [email protected].
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.